title: [Inspra and the drug benefits board: What is the role of the drug committees?].
authors.affiliation: mikael.hoffmann@lio.se
authors.forename: Mikael
authors.initials: M
authors.lastname: Hoffmann
authors.forename: Rune
authors.initials: R
authors.lastname: Dahlqvist
authors.forename: Lars-Ake
authors.initials: LA
authors.lastname: Levin
authors.forename: Bengt
authors.initials: B
authors.lastname: Silfverhielm
authors.forename: Ingmarie
authors.initials: I
authors.lastname: Skoglund
authors.forename: Ellen
authors.initials: E
authors.lastname: Vinge
mesh_terms: D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004346:Drug Information Services; D000077545:Eplerenone; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D010606:Pharmacy and Therapeutics Committee; D017410:Practice Guidelines as Topic; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000191:economics* / Q000627:therapeutic use; D013548:Sweden
chemical_list: D013148:Spironolactone; D000077545:Eplerenone